Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset. [PDF]
Schedler NC +3 more
europepmc +1 more source
Real-world cost avoidance associated with bevacizumab biosimilar adoption in a tertiary public hospital in Ecuador: a cost-minimization and budget impact analysis. [PDF]
RodrÃguez S +4 more
europepmc +1 more source
Treatment trajectories and patterns following non-medical switching to biosimilar adalimumab in patients with hidradenitis suppurativa: a retrospective observational multicenter study from Saudi Arabia. [PDF]
Alamer A +4 more
europepmc +1 more source
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025). [PDF]
Gilbert Farrar K +4 more
europepmc +1 more source
FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. [PDF]
Delvadia PR +17 more
europepmc +1 more source
From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development. [PDF]
Ribes S +4 more
europepmc +1 more source
Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same. [PDF]
Park JP, Oh H, Woollett GR.
europepmc +1 more source
Expanding Patient Access to Advanced Therapies. [PDF]
Guillen E, Hidalgo-Simon A.
europepmc +1 more source
Demonstrating interchangeability and biosimilarity for US biosimilars [PDF]
openaire +1 more source

